JAZZ - Jazz Pharmaceuticals to buy global rights to KRAS inhibitor program
2024-02-07 03:41:50 ET
More on Jazz Pharmaceuticals
- Updated View On Jazz Pharmaceuticals' 2025 Goals
- Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market Undervaluation
- Jazz Pharma PTSD mid-stage trial fails to meet main goal, stock slips after hours
- Jazz presents encouraging Phase 2 data for breast cancer treatment
- Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals